603456.SS SHH
Zhejiang Jiuzhou Pharmaceutical Co., Ltd
1W: +3.4%
1M: +10.3%
3M: +15.4%
YTD: -7.0%
1Y: -7.8%
3Y: -31.9%
5Y: -58.0%
¥16.75 ($2.50)
+0.49 (+3.01%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$5.2B
-6.6% ▼
5Y CAGR: +20.7%
Gross Profit
$1.6B
-20.5% ▼
5Y CAGR: +18.2%
Operating Income
$732M
-37.7% ▼
5Y CAGR: +20.7%
Net Income
$606M
-41.3% ▼
5Y CAGR: +20.6%
EPS (Diluted)
$0.68
-41.8% ▼
5Y CAGR: +17.9%
EBITDA
$1.1B
-25.0% ▼
5Y CAGR: +18.2%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $2.6B | $4.1B | $5.4B | $5.5B | $5.2B |
| YoY Growth | +31.3% | +53.5% | +34.0% | +1.4% | -6.6% |
| Cost of Revenue | $1.7B | $2.7B | $3.6B | $3.5B | $3.6B |
| Gross Profit | $956M | $1.3B | $1.8B | $2.0B | $1.6B |
| Gross Margin | 36.1% | 32.4% | 33.5% | 36.2% | 30.8% |
| R&D Expenses | $114M | $173M | $287M | $331M | $315M |
| SG&A Expenses | $340M | $383M | $480M | $524M | $513M |
| Operating Expenses | $500M | $563M | $714M | $823M | $857M |
| Operating Income | $456M | $754M | $1.1B | $1.2B | $732M |
| Operating Margin | 17.2% | 18.5% | 20.3% | 21.3% | 14.2% |
| Interest Expense | $45M | $27M | $24M | $25M | $21M |
| Income Before Tax | $450M | $745M | $1.1B | $1.2B | $731M |
| Tax Expense | $70M | $111M | $183M | $149M | $124M |
| Net Income | $381M | $634M | $921M | $1.0B | $606M |
| Net Margin | 14.4% | 15.6% | 16.9% | 18.7% | 11.7% |
| EPS (Diluted) | $0.47 | $0.76 | $1.11 | $1.16 | $0.68 |
| EBITDA | $719M | $1.0B | $1.4B | $1.5B | $1.1B |
| Shares Outstanding | 803M | 834M | 830M | 891M | 898M |